Trial Profile
Clinical protocol for a multicenter, double-blind, randomized, placebo controlled, comparison of the efficacy and safety of Bextra (valdecoxib) 10 mg once daily and naproxen 500 mg twice daily in treating the signs and symptoms of rheumatoid arthritis (RA) in a severe RA population
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Valdecoxib (Primary) ; Naproxen
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 20 Jul 2008 Actual study completion date (1 Jan 2005) added as reported by ClinicalTrials.gov.
- 16 Apr 2008 New trial record.